Research Paper
Spinal cord stimulation for heart failure: DEFEAT-HF 2-year outcomes
PubMed4/12/2026·04/12/26🌐 USA
Summary
DEFEAT-HF 2-year follow-up of 256 refractory heart failure patients receiving SCS showed sustained +87m 6-minute walk improvement and a 34% reduction in hospitalizations versus medical therapy with no device-related serious adverse events.
Why it matters
These outcomes establish SCS as a credible therapeutic option for heart failure, opening a large new market for neurostimulation companies beyond the traditional pain and movement disorder indications.
#BCI#Neural Interfaces#Neurostimulation#Spinal Cord Stimulation
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in